Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics

Research output: Contribution to journalReview articlepeer-review

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic neoplasm with a dismal prognosis and no standard therapy. In the past, its cellular ontogenesis was obscure, and BPDCN had been erroneously named CD56+/TdT+ blastic NK cell tumor and CD4+/CD56+ hematodermic neoplasm. Finally, in 2008, the BPDCN was correctly recognized as a neoplasm deriving from the malignant transformation of plasmacytoid dendritic cell precursors and classified among the myeloid neoplasms. Since then, the understanding of BPDCN biology has improved rapidly: the DNA mutational status of BPDCN has been extensively investigated revealing a spectrum perfectly resembling its myeloid lineage derivation.

Original languageEnglish
Pages (from-to)511-521
Number of pages11
JournalHematology/Oncology Clinics of North America
Volume34
Issue number3
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Azacitidine
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
  • BRD4
  • Epigenetics
  • Methylation
  • NGS

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics'. Together they form a unique fingerprint.

Cite this